These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [An overview of the pharmacokinetics and pharmacodynamics of rocuronium bromide]. Iwasaki H Masui; 2006 Jul; 55(7):826-33. PubMed ID: 16856542 [TBL] [Abstract][Full Text] [Related]
24. Repeated doses of rocuronium bromide administered to cirrhotic and control patients receiving isoflurane. A clinical and pharmacokinetic study. Servin FS; Lavaut E; Kleef U; Desmonts JM Anesthesiology; 1996 May; 84(5):1092-100. PubMed ID: 8624003 [TBL] [Abstract][Full Text] [Related]
25. Rocuronium bromide in the ICU: dose finding and pharmacokinetics. Khuenl-Brady KS; Sparr H; Pühringer F; Agoston S Eur J Anaesthesiol Suppl; 1995 Sep; 11():79-80. PubMed ID: 8557012 [TBL] [Abstract][Full Text] [Related]
26. Neuromuscular transmission: new concepts and agents. de Boer HD J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537 [TBL] [Abstract][Full Text] [Related]
27. Priming rapacuronium: a comparison with rocuronium and mivacurium. Steinberg D Acta Cient Venez; 2003; 54(2):115-20. PubMed ID: 14976782 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of rapacuronium in patients with cirrhosis. Duvaldestin P; Slavov V; Rebufat Y Anesthesiology; 1999 Nov; 91(5):1305-10. PubMed ID: 10551581 [TBL] [Abstract][Full Text] [Related]
29. ORG 9426, succinylcholine or vecuronium: which agent provides "overall superiority" for short outpatient procedures. Ginsburg R; Lippmann M Anesth Analg; 1993 Apr; 76(4):904-5. PubMed ID: 8096683 [No Abstract] [Full Text] [Related]
30. Neuromuscular pharmacodynamics of rocuronium in patients with major burns. Han T; Kim H; Bae J; Kim K; Martyn JA Anesth Analg; 2004 Aug; 99(2):386-92, table of contents. PubMed ID: 15271712 [TBL] [Abstract][Full Text] [Related]
35. Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Cembala TM; Sherwin JD; Tidmarsh MD; Appadu BL; Lambert DG Br J Pharmacol; 1998 Nov; 125(5):1088-94. PubMed ID: 9846649 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of pipecurium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. Tassonyi E; Szabó G; Vereczkey L Arzneimittelforschung; 1981; 31(10):1754-6. PubMed ID: 6274362 [TBL] [Abstract][Full Text] [Related]
37. Studies on the interaction of steroidal neuromuscular blocking drugs with cardiac muscarinic receptors. Appadu BL; Lambert DG Br J Anaesth; 1994 Jan; 72(1):86-8. PubMed ID: 7906535 [TBL] [Abstract][Full Text] [Related]
38. Skin reactions to intradermal neuromuscular blocking agent injections: a randomized multicenter trial in healthy volunteers. Mertes PM; Moneret-Vautrin DA; Leynadier F; Laxenaire MC Anesthesiology; 2007 Aug; 107(2):245-52. PubMed ID: 17667568 [TBL] [Abstract][Full Text] [Related]
39. Safety aspects of non-depolarizing neuromuscular blocking agents with special reference to rocuronium bromide. Mirakhur RK Eur J Anaesthesiol Suppl; 1994; 9():133-40. PubMed ID: 7523105 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of rocuronium during the three stages of liver transplantation. Fisher DM; Ramsay MA; Hein HA; Marcel RJ; Sharma M; Ramsay KJ; Miller RD Anesthesiology; 1997 Jun; 86(6):1306-16. PubMed ID: 9197300 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]